LungFX Device
Lung Bioengineering, Inc. · Decision date Oct 16, 2026
What did the FDA approve?
The FDA record lists decision APPR dated 2026-10-16 for supplement P240033/S001, a Normal 180 Day Track No User Fee submission whose reason is 'Postapproval Study Protocol.' The statement describes approval of the protocol for the post-approval study, submitted to comply with conditions of approval in the order for P240033. The changed item is a study protocol document, not the device's original approval; the S001 identifier ties it to PMA P240033 for a normothermic preservation system for transplantation of initially unacceptable donor lungs.
The statement reports the protocol's purpose as satisfying approval conditions, which is not independent proof of safety or clinical effectiveness. Absent details include the study design, endpoints, sample size, follow-up duration, and the specific conditions the protocol addresses; the source does not supply them. The specialty fields list Gastroenterology, Urology, while the device category describes lung transplantation, and the record does not reconcile that.
FDA approval order statement
Approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240033.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Oct 16, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P240033/S001
- Regulatory pathway
- PMA supplement
- Applicant
- Lung Bioengineering, Inc.
- Product code
- PHO
- Decision code
- APPR
- Decision date
- Oct 16, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Normothermic preservation system for transplantation of initially unacceptable donor lungs.
- Applicant
- Lung Bioengineering, Inc.
- Product code
- PHO
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P240033. Subsequent supplements may change the device or its indications.
FDA decision timeline
P240033 · Original PMA
LungFX device
P240033/S001 received
Application receipt date recorded by FDA.
P240033/S002 · Related supplement
LungFX Device
P240033/S001 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P240033. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240033
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
LungFX deviceP240033 | Lung Bioengineering, Inc. | PMA approval | Jun 22, 2026 | FDA |
LungFX DeviceP240033/S002 | Lung Bioengineering, Inc. | PMA supplement | Oct 16, 2026 | FDA |
Explore the linked device profile
Other records with product code PHO
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
| Traferox Technologies, Inc. | PMA supplement | Oct 30, 2026 | FDA | |
XPS with Steen Solution PerfusateP180014/S014 | Xvivo Perfusion, Inc. | PMA supplement | Sep 16, 2026 | FDA |
TorEx Lung Perfusion SystemP250025 | Traferox Technologies, Inc. | PMA approval | Jul 15, 2026 | FDA |
| Xvivo Perfusion, Inc. | PMA approval | Apr 26, 2019 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Lung Bioengineering, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Lb1 Bldg., 1015 Spring St., Silver Spring, MD, 20910
Sources and methodology
- Original FDA record: P240033/S001
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




